SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Lord Abbett Private Credit Fund issued approximately 1.37 million common shares for $34.1 million ($24.86 per share) to accredited investors pursuant to subscription agreements, relying on Section 4(a)(2) and Regulation D exemptions from Securities Act registration.
View raw filing on EDGAR →The Company issued approximately 169,368 common shares for $4.2 million to accredited investors pursuant to subscription agreements, relying on Section 4(a)(2) and Regulation D exemptions from Securities Act registration.
View raw filing on EDGAR →Apex Critical Metals Corp. entered into an underwriting agreement dated October 22, 2026 for a registered public offering of 2,400,000 common shares (400,000 ADSs) with an additional 360,000 shares (60,000 ADSs) available under an over-allotment option, led by underwriters including Maxim Group LLC.
View raw filing on EDGAR →Apex Critical Metals closed an underwritten public offering of 400,000 ADSs (representing 2.4 million common shares) at US$4.65 per ADS, generating gross proceeds of US$1.86 million pursuant to an effective Form F-10 shelf registration statement. The underwriter received a 45-day greenshoe option to purchase an additional 60,000 ADSs, and was granted representative warrants exercisable at US$5.81 per ADS through October 23, 2030, creating additional dilution potential for existing shareholders.
View raw filing on EDGAR →Cizzle Brands announces an underwritten public offering of common shares in the United States pursuant to a Form F-10 registration statement filed with the SEC, with concurrent offering in Canada under the LIFE Exemption. The offering involves issuance of new equity securities with pricing and terms to be determined at market. This is a material dilutive equity issuance that would affect a reasonable investor's assessment of ownership and capital structure.
View raw filing on EDGAR →Alpine Income Property Trust disclosed a Preferred Offering of 8.00% Series A Cumulative Redeemable Preferred Stock with net proceeds to be contributed to the Operating Partnership in exchange for Series A Preferred Units, representing a material capital raise with liquidation preference of $25.00 per unit.
View raw filing on EDGAR →Alpine Income Property Trust established two at-the-market (ATM) offering programs: a Preferred Shares ATM program for up to $35 million and a Common Stock ATM program for up to $150 million, representing an aggregate potential dilutive issuance of $185 million in registered equity.
View raw filing on EDGAR →Traws Pharma entered into a Common Stock Purchase Agreement with Roth Principal Investments establishing an at-the-market (ATM) offering facility allowing the Company to sell up to $50,000,000 in newly issued common stock over a 36-month period at a 6% discount to VWAP, with multiple purchase mechanisms and an unregistered private placement to accredited investors under Section 4(a)(2) and Rule 506(b) exemptions.
View raw filing on EDGAR →BlackRock Private Credit Fund disclosed an unregistered private placement of 250,520.94 Institutional Class Shares for $5,894,457 to feeder vehicles, relying on Section 4(a)(2) and Regulation S exemptions. This capital raise represents dilution to existing shareholders.
View raw filing on EDGAR →The exhibit discloses an unregistered private placement of 2,751,789 Class A ordinary shares at $1.8170 per share for $5,000,000 in aggregate gross proceeds, relying on Section 4(a)(2) of the Securities Act and Regulation D Rule 506(b). This is a classic dilutive equity issuance. The transaction also involves a related-party component (Yang Investor controlled by CEO Dr. Tingjun Yang subscribing for 1,157,823 shares), which was reviewed and approved by the Audit Committee and Board, but the primary event is the unregistered equity sale itself.
View raw filing on EDGAR →The Company disclosed the sale of 16,740 Class D Common Shares for $462,000 under a continuous private placement offering of up to $2.165 billion in unregistered equity securities, conducted pursuant to Section 4(a)(2) and Regulation D Rule 506(c). This is a classic dilutive issuance of unregistered equity that would materially affect investor assessment of share dilution and capital structure.
View raw filing on EDGAR →Bolt completed an unregistered private placement of $120 million in Series D convertible preferred stock and warrants to purchase up to an additional $60 million, offered and sold in reliance on Section 4(a)(2) and Regulation D. Post-transaction, PIPE investors will own approximately 41.4% of common stock on a fully-diluted basis.
View raw filing on EDGAR →The filing discloses an unregistered sale of equity securities (common stock) pursuant to Item 3.02, with an aggregate offering price of $16.7 million. The shares are being issued under subscription agreements to existing investors via capital calls, exempt from Securities Act registration under Section 4(a)(2) and Regulation D. This is a classic dilutive issuance of unregistered equity to raise capital.
View raw filing on EDGAR →Vista Credit Strategic Lending Corp. completed an unregistered sale of 371,804.601 shares of Class I common stock for $7.2 million to accredited investors and non-U.S. persons, relying on Section 4(a)(2) and Regulation D/S exemptions.
View raw filing on EDGAR →EQT Private Equity Company LLC disclosed an unregistered sale of equity securities (663,060 shares across multiple classes) for approximately $19.1 million in aggregate consideration as of October 1, 2026. The offering was conducted under Section 4(a)(2) and Regulations D and S, which are classic exemptions for private placements. This is a textbook dilutive issuance under Item 3.02, and the cumulative $880+ million raised since inception demonstrates material capital-raising activity that would affect investor assessment of the company's capitalization and ownership structure.
View raw filing on EDGAR →EQT Infrastructure sold approximately $92.1 million in unregistered Investor Shares across multiple share classes to third-party investors as of October 1, 2026, relying on Section 4(a)(2) and Regulations D and S exemptions. This is a classic dilutive private placement of equity securities. The filing explicitly discloses this as part of a continuous private offering that has raised approximately $1.1 billion since inception in February 2026, making it material to investors' assessment of ownership dilution and capital structure.
View raw filing on EDGAR →First Eagle Private Credit Fund sold 416,844 unregistered Class I common shares for $9.8 million to a feeder vehicle, relying on Section 4(a)(2) and Regulation S exemptions from Securities Act registration.
View raw filing on EDGAR →Valor Energy entered into a securities purchase agreement on October 19, 2026, to sell 2,145,923 unregistered shares of common stock at $2.33 per share for approximately $5 million in gross proceeds. The offering is conducted under Regulation D exemption with accredited and sophisticated investors, and Item 3.02 explicitly incorporates the disclosure as an unregistered equity sale. This is a classic private placement that dilutes existing shareholders and raises capital.
View raw filing on EDGAR →WEBUY GLOBAL LTD consummated a share subscription on October 22, 2026, issuing 138,370 Class B ordinary shares to Bin Xue at US$0.68 per share. This issuance represents approximately 14.7% of aggregate voting power and increases Bin Xue's total beneficial ownership to 47.4% of voting power. This is a material dilutive equity issuance that would affect a reasonable investor's assessment of ownership structure and voting control.
View raw filing on EDGAR →The 6-K discloses an Exchange Agreement (October 22, 2026) whereby the Company exchanged a $10,000 partitioned note for 24,509 ordinary shares at $0.408 per share, issued under Section 3(a)(9) exemption. Although characterized as a conversion under the existing Note rather than a standalone dilutive issuance, the exchange results in new equity issuance to an existing investor and represents a material capital event affecting share count and ownership structure.
View raw filing on EDGAR →RMX Industries completed an unregistered sale of equity securities to Vanquish under a Purchase Agreement, exempt from Securities Act registration under Section 4(a)(2) and Regulation D Rule 506(b), representing a private placement to an accredited investor.
View raw filing on EDGAR →Item 3.02 discloses the issuance of 5,332,617 restricted shares of common stock to Mandragola Ltd. upon cashless exercise of warrants issued in connection with the DFSL acquisition. The shares were issued in reliance on Section 4(a)(2) of the Securities Act and are restricted securities under Rule 144, meeting the definition of an unregistered equity issuance. This represents a material dilutive event affecting the capital structure and ownership percentages of existing shareholders.
View raw filing on EDGAR →The 6-K discloses an amendment to an existing At-The-Market (ATM) offering agreement with H.C. Wainwright, decreasing the maximum aggregate offering price to $2,006,769 for sale of American Depositary Shares representing ordinary shares. This constitutes a dilutive equity issuance under a registered shelf offering, material to investors assessing capital structure and shareholder dilution risk.
View raw filing on EDGAR →The 6-K references Exhibit 99.1 titled "Proposed issue of securities - ATH," indicating a planned equity issuance by Alterity Therapeutics. Although the exhibit itself is not furnished in the body, the cover page explicitly lists this as the subject matter being submitted. For a development-stage biotech company, a securities issuance is typically material to investors assessing capital structure and dilution risk.
View raw filing on EDGAR →Zevia entered into a Securities Purchase Agreement with GP Investments to issue $20 million of Series A Senior Convertible Preferred Stock (15,000 shares at closing, 5,000 shares deferred), convertible into Class A Common Stock at 120% of the 10-day VWAP, subject to a 19.99% conversion cap. The transaction was structured as a private placement under Section 4(a)(2) and Regulation D Rule 506, and the company explicitly acknowledged the dilutive effect on existing shareholders upon conversion.
View raw filing on EDGAR →Picard Medical entered into a Warrant Amendment and Exchange Agreement on October 20, 2026, whereby warrant holders surrendered warrants exercisable for 8,187,766 shares in exchange for 200,000 shares of common stock issued under Section 3(a)(9) exemption. This unregistered equity issuance represents a material dilutive capital event affecting the company's share count and ownership structure.
View raw filing on EDGAR →CBL International Limited completed a private placement of 400,000 Class B ordinary shares at US$2.12 per share (a 30% discount to market) on October 23, 2026, raising US$848,000 in gross proceeds. The placement also included warrants (Options) to purchase an additional 200,000 shares at US$3.18 per share. This is a classic dilutive unregistered equity issuance under Section 4(a)(2) and Regulation S, materially affecting existing shareholders through immediate dilution and potential further dilution from warrant exercise.
View raw filing on EDGAR →Fusemachines amended a Common Stock Purchase Warrant held by Meteora Capital Partners, materially reducing the exercise price from a floor of $0.85 per share to a floating average VWAP price and shortening the warrant term to October 2027. This amendment makes the warrant substantially more likely to be exercised and dilutive to existing shareholders, similar to a dilutive equity issuance. While not a new issuance per se, the amendment of warrant terms to reduce exercise price and increase exercise likelihood is a material capital structure event affecting shareholder dilution.
View raw filing on EDGAR →The exhibit announces the closing of an underwritten public offering of 400,000 ADSs (representing 2.4 million common shares) at US$4.65 per ADS, generating US$1.86 million in gross proceeds. This is a registered equity issuance that dilutes existing shareholders and raises capital for the company's exploration activities. The offering was made pursuant to an effective Form F-10 shelf registration statement and represents a material capital-raising event for a mineral exploration company.
View raw filing on EDGAR →The filing discloses an at-the-market (ATM) offering under a Sales Agreement with Needham & Company, LLC, with the Company selling 15,785,757 shares during October 2026 for approximately $4.7 million gross proceeds. This represents a dilutive equity issuance material to investors, as it increases share count by approximately 45% relative to the 19.2 million shares outstanding as of the filing date, and raises capital through unregistered or registered equity sales typical of dilutive issuances.
View raw filing on EDGAR →The filing discloses the automatic conversion of 372,976 shares of Series A and Series B Convertible Preferred Stock into 8,077,043 shares of Common Stock upon effectiveness of the S-3 registration statement on October 23, 2026. This represents a substantial dilution to existing common shareholders—the outstanding common stock increased from approximately 5.2 million to 13.3 million shares (a 155% increase). While technically a conversion rather than a new issuance, the economic effect is a material dilutive event that would affect a reasonable investor's assessment of ownership and voting power.
View raw filing on EDGAR →Zai Lab entered into a Securities Purchase Agreement on October 22, 2026, to sell 11,340,000 ADSs at $22.04 per ADS in a private placement generating approximately $250 million in gross proceeds. The company also entered into a Registration Rights Agreement requiring registration of the resold securities within 15 days of closing. This unregistered equity issuance to accredited investors is a classic PIPE transaction material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →Evernorth entered into a Common Stock Purchase Agreement with CF Principal Investments LLC establishing a committed equity facility allowing the Company to sell up to 5,218,935 newly issued shares of Class A common stock at its discretion. The facility is structured as a private placement of unregistered securities under Section 4(a)(2) exemption, with the Company paying upfront and ongoing fees to access this capital source.
View raw filing on EDGAR →Edgemode sold an unsecured convertible promissory note for $133,000 net proceeds in a private placement under Section 4(a)(2). The convertible feature with a 61% discount to the lowest trading price, high default interest (22% per annum), and default acceleration multiplier (150-200% of principal) indicate this is primarily equity-like financing rather than traditional debt, characteristic of dilutive capital-raising at small-cap issuers.
View raw filing on EDGAR →Unusual Machines issued 1,792,012 shares to Mr. Barnard Representative under Section 4(a)(2) and 137,260 shares to Rotor Lab Sellers as earnout consideration under Regulation S, representing unregistered private placements of common stock that dilute existing shareholders.
View raw filing on EDGAR →Arcus Biosciences completed a public offering of 16,428,572 shares of common stock (including full exercise of the underwriters' option) at $17.50 per share, raising approximately $269.7 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and represents a significant capital raise for the company.
View raw filing on EDGAR →UWM Holdings announced a rights offering to raise up to $400 million through Class A Common Stock at a discounted subscription price or junior perpetual preferred stock plus warrants, with a backstop agreement from CEO Mat Ishbia and Oaktree Capital ensuring full funding and resulting in significant dilution to existing shareholders.
View raw filing on EDGAR →Blue Owl Credit Income Corp. completed an unregistered sale of 464,303 shares of Class I common stock for approximately $4.26 million, exempt under Section 4(a)(2) and Regulation S, representing a dilutive equity issuance to feeder vehicles.
View raw filing on EDGAR →Blue Owl Technology Income Corp. completed an unregistered private placement of 505,374 shares of Class I common stock to feeder vehicles for approximately $4.98 million, exempt under Section 4(a)(2) and Regulation S.
View raw filing on EDGAR →The filing discloses an unregistered sale of 104,054 common shares for $2,726,227 pursuant to Section 4(a)(2) and Regulation D/S under the Securities Act. This is a classic dilutive issuance of equity securities outside registered offerings, which materially affects existing shareholders' ownership percentages and is a key disclosure for investors assessing capital structure changes.
View raw filing on EDGAR →TPG Private Equity Opportunities, L.P. sold $73.1 million in unregistered limited partnership units (Class I, S, and F) on October 1, 2026, as part of a continuous private offering exempt under Section 4(a)(2) and Regulation D, representing a material dilutive issuance to third-party investors and through a feeder vehicle for tax-exempt and non-U.S. investors.
View raw filing on EDGAR →Golub Capital Private Income Fund S issued 28,718 common shares of beneficial interest for $692,400 as of October 1, 2026, pursuant to subscription agreements and exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →Golub Capital Private Income Fund I issued 10,185 common shares of beneficial interest pursuant to subscription agreements, exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →This press release announces an underwritten public offering of 400,000 ADSs (representing 2.4 million common shares) at US$4.65 per ADS, raising US$1.86 million gross proceeds. The offering is being made pursuant to an effective Form F-10 shelf registration and is expected to close on October 23, 2026. This is a material dilutive equity issuance that would affect a reasonable investor's assessment of ownership dilution and capital structure, particularly for a mineral exploration company raising capital for working capital and advancing its Rift Rare Earth Project.
View raw filing on EDGAR →The Company issued 75,000 Class B Ordinary Shares to Jinghai Jiang (the Chairman, CEO, and COO) on October 21, 2026, pursuant to a securities purchase agreement. The issuance was made under Section 4(a)(2) of the Securities Act of 1933 (a private placement exemption), and following the issuance, the Buyer holds 100% of Class B shares representing approximately 35% of total voting power. This is a dilutive private placement of equity securities to an insider, material to investors assessing ownership structure and control.
View raw filing on EDGAR →Data I/O Corporation issued $3 million in unregistered common stock to V-TEK's selling shareholders as part of the acquisition consideration, relying on Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →Disc Medicine announced and priced an underwritten public offering of 6,000,000 shares of common stock at $75.00 per share, raising approximately $450 million in gross proceeds (with expected net proceeds of approximately $422.4 million), plus a 30-day underwriter option to purchase an additional 900,000 shares. This registered equity issuance is material to existing shareholders due to dilution and represents a significant capital raise for the clinical-stage biopharmaceutical company.
View raw filing on EDGAR →The press release announces a voluntary pause of an at-the-market (ATM) equity offering program. While the pause itself is a suspension rather than an issuance, it relates directly to a dilutive equity offering mechanism. The disclosure is material because it signals the Company's capital-raising strategy and market positioning; however, the pause (rather than an active sale or new issuance) creates some ambiguity about whether this is best classified as a dilutive_issuance event or a strategic operational decision. The ATM program remains in place and could resume, making this a material capital-structure disclosure.
View raw filing on EDGAR →The Company issued a Series B warrant to purchase 125,000 shares of Common Stock as consideration for waiving restrictions on its at-the-market offering. This is a dilutive equity issuance to an institutional investor under Section 4(a)(2) exemption. While the primary transaction is a waiver agreement, the material economic substance is the issuance of equity securities (warrants) that will dilute existing shareholders upon exercise, which is characteristic of dilutive_issuance events.
View raw filing on EDGAR →The 6-K discloses two capital-raising transactions: (1) an at-the-market (ATM) offering of up to $50 million in Class A Ordinary Shares entered into on October 22, 2026, and (2) a closed notes offering from September 10, 2026, involving $850,000 in convertible promissory notes plus 100,000 commitment shares. Both transactions involve dilutive equity issuances to raise capital. The ATM agreement with Chaince Securities and the convertible notes with institutional investors are material financing events that would affect a reasonable investor's assessment of the registrant's capital structure and dilution.
View raw filing on EDGAR →